Skip to main content
SpringerLink
Log in
Book cover

Antiphospholipid Syndrome pp 167–179Cite as

Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome

  • Chapter
  • First Online:

  • 655 Accesses

Abstract

The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with the persistent presence of circulating antiphospholipid antibodies (aPL): lupus anticoagulant test, anticardiolipin antibodies, and/or anti ß2 glycoprotein I antibodies in medium to high titers. The management of thrombosis in patients with APS is subject of controversy. In the setting of the 13th International Congress on Antiphospholipid Antibodies, held in Galveston in April 2010, an international Task Force composed of clinicians and researchers with experience in the field jointly elaborated a consensus document on the primary and secondary thromboprophylaxis in individuals with aPL.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus. 2011;20:206–18.

    Article  PubMed  CAS  Google Scholar 

  2. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus. 2010;19:440–5.

    Article  PubMed  CAS  Google Scholar 

  3. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–32.

    Article  PubMed  CAS  Google Scholar 

  4. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102:2717–23.

    Article  PubMed  CAS  Google Scholar 

  5. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid ­antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006;33:2214–21.

    PubMed  CAS  Google Scholar 

  6. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, De Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol. 2009;8:998–1005.

    Article  PubMed  CAS  Google Scholar 

  7. Martínez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, et al. Transiently positive anticardiolipin antibodies do not increase the risk of thrombosis in patients with systemic lupus erythematosus. Lupus. 2007;16:810–6.

    Article  PubMed  Google Scholar 

  8. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29–36.

    Article  PubMed  Google Scholar 

  9. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. 2007;110:1178–83.

    Article  PubMed  CAS  Google Scholar 

  10. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-­glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3:1231–8.

    Article  PubMed  CAS  Google Scholar 

  11. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147–52.

    PubMed  CAS  Google Scholar 

  12. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237–42.

    Article  PubMed  CAS  Google Scholar 

  13. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009;113:985–94.

    Article  PubMed  CAS  Google Scholar 

  14. Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndome. Q J Med. 2000;93:523–30.

    Article  CAS  Google Scholar 

  15. Danowski A, de Azevedo MN, de Souza Papi JA, Petri MA. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36:1195–9.

    Article  PubMed  CAS  Google Scholar 

  16. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:924–9.

    Article  CAS  Google Scholar 

  17. Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009;68:397–9.

    Article  PubMed  CAS  Google Scholar 

  18. Girón-González JA, García del Río E, Rodríguez C, Rodríguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560–7.

    PubMed  Google Scholar 

  19. Manzi S, Meilhn EN, Rairie JE, et al. Age specific incidence rates of myocardial infarction and angina in women with SLE: comparison with the Framingham study. Am J Epidemiol. 1997;145:408–15.

    Article  PubMed  CAS  Google Scholar 

  20. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331–7.

    Article  PubMed  CAS  Google Scholar 

  21. Mok CC, Tang S, To C, Petri MA. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005;52:2774–82.

    Article  PubMed  Google Scholar 

  22. Kaiser R, Cleveland C, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68:238–41.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530–6.

    Article  PubMed  CAS  Google Scholar 

  24. Silver RM, Draper ML, Scott JR, Lyon JL, Reading J, Branch DW. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol. 1994;83:372–7.

    PubMed  CAS  Google Scholar 

  25. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.

    Article  PubMed  CAS  Google Scholar 

  26. Francès C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52:1785–93.

    Article  PubMed  Google Scholar 

  27. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–73.

    Article  PubMed  Google Scholar 

  28. De Laat B, Derksen RH, Reber G, et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost. 2011;9:149–53.

    Article  PubMed  CAS  Google Scholar 

  29. Detkov D, Gil-Aguado A, Lavilla P, Cuesta MV, Fontán G, Pascual-Salcedo D. Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? Lupus. 1999;8:430–8.

    Article  PubMed  CAS  Google Scholar 

  30. Lee EY, Lee CK, Lee TH, et al. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res. 2003;111:29–32.

    Article  PubMed  CAS  Google Scholar 

  31. Sailer T, Zoghlami C, Kurz C, et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost. 2006;95:796–801.

    PubMed  CAS  Google Scholar 

  32. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost. 2005;3:1160–5.

    Article  PubMed  CAS  Google Scholar 

  33. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res. 2009;123:482–7.

    Article  PubMed  CAS  Google Scholar 

  34. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–95.

    Article  PubMed  Google Scholar 

  35. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.

    Article  PubMed  CAS  Google Scholar 

  36. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.

    Article  PubMed  CAS  Google Scholar 

  37. Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med. 2004;164:668–73.

    Article  PubMed  CAS  Google Scholar 

  38. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332–8.

    Article  PubMed  CAS  Google Scholar 

  39. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:454–545.

    Article  CAS  Google Scholar 

  40. Prandoni P, Prins MH, Lensing AW, AESOPUS Investigators, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med. 2009;50:577–85.

    Article  Google Scholar 

  41. Palareti G, Cosmi B, Legnani C, PROLONG Investigators, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780–9.

    Article  PubMed  CAS  Google Scholar 

  42. Cosmi B, Legnani C, Tosetto A, PROLONG Investigators (on behalf of Italian Federation of Anticoagulation Clinics), et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood. 2010;115:481–8.

    Article  PubMed  CAS  Google Scholar 

  43. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–7.

    Article  PubMed  CAS  Google Scholar 

  44. Levine SR, Brey RL, Tilley BC, APASS Investigators, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576–84.

    Article  PubMed  CAS  Google Scholar 

  45. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133: 630S–69.

    Article  PubMed  CAS  Google Scholar 

  46. Neville C, Rauch J, Kassis J, et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost. 2009;101:100–7.

    PubMed Central  PubMed  CAS  Google Scholar 

  47. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32.

    Article  PubMed  CAS  Google Scholar 

  48. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.

    Article  PubMed  Google Scholar 

  49. Tan BE, Thong BY, Shivananda S, Han WW, Chng HH. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus. 2009;18:752–8.

    Article  PubMed  CAS  Google Scholar 

  50. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2009;7:15–8.

    PubMed Central  PubMed  Google Scholar 

  51. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.

    Article  PubMed  CAS  Google Scholar 

  52. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2study): a randomised controlled trial. Lancet. 2002;360:109–13.

    Article  PubMed  Google Scholar 

  53. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714–8.

    Article  PubMed  CAS  Google Scholar 

  54. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.

    Article  PubMed  CAS  Google Scholar 

  55. Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus. 2010;19:475–85.

    Article  PubMed  CAS  Google Scholar 

  56. Pericleous C, Ioannou Y. New therapeutic targets for the antiphospholipid syndrome. Expert Opin Ther Targets. 2010;14:1291–9.

    Article  PubMed  CAS  Google Scholar 

  57. Cervera R, Tektonidou M, Espinosa G, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20:165–73.

    Article  PubMed  CAS  Google Scholar 

  58. Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schünemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:123S–31.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The members of the “Task Force on Management of Antiphospholipid Syndrome” that contributed to the discussions that are presented in this chapter are as follows (in addition to the authors): Robin Brey (University of Texas Health Science Center, San Antonio, TX, USA), Mark Crowther (McMaster University, Hamilton, Ontario, Canada), Ronald Derksen (University Medical Centre, Utrecht, The Netherlands), Doruk Erkan (Hospital for Special Surgery, New York, NY, USA), Steve Krilis (St. George Hospital, University of New South Wales, Sydney, Australia), Sam Machin (University College London Hospitals, London, UK), and Silvia Pierangeli (University of Texas Medical Branch, Galveston, TX).

Author information

Authors and Affiliations

  1. Autoimmune Diseases Research Unit, Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, PZA CRUCES SN, Barakaldo, Bizkaia, 48903, Spain

    Guillermo Ruiz-Irastorza MD, PhD & Ioana Ruiz-Arruza MD

  2. University Hospital, University of Padova, Padova, Italy

    Vittorio Pengo MD

  3. First Department of Internal Medicine, University of Athens Medical School, Athens, Greece

    Maria G. Tektonidou MD, PhD

  4. Lupus Research Unit, St. Thomas’ Hospital, King’s College London, London, UK

    María José Cuadrado MD, PhD & Munther A. Khamashta MD, PhD

Authors
  1. Guillermo Ruiz-Irastorza MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vittorio Pengo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria G. Tektonidou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ioana Ruiz-Arruza MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. María José Cuadrado MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Munther A. Khamashta MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillermo Ruiz-Irastorza MD, PhD .

Editor information

Editors and Affiliations

  1. The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, USA

    Doruk Erkan

  2. University of Texas Medical Branch, 301 University Boulevard, Galveston, 77555-0883, Texas, USA

    Silvia S. Pierangeli

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ruiz-Irastorza, G., Pengo, V., Tektonidou, M.G., Ruiz-Arruza, I., Cuadrado, M.J., Khamashta, M.A. (2012). Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. In: Erkan, D., Pierangeli, S. (eds) Antiphospholipid Syndrome. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3194-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3194-7_11

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-3193-0

  • Online ISBN: 978-1-4614-3194-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation